GNA1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis
AssigneeChildren's Hospital & Research Center at Oakland
InventorsDan M. Granoff, Victor Chen-Hsi Hou
Life of this patent
Estimating the term…
Abstract
The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
Claims21
-52. (canceled)
A composition comprising:
- isolated antigenic vesicles prepared from a first Neisseria meningitidis (N. meningitidis),
- wherein the first N. meningitidis is genetically modified to disrupt production of an endogenous GNA1870 polypeptide so that the endogenous GNA1870 is not present at detectable levels in the isolated antigenic vesicles and to express at least one heterologous full length meningococcal GNA1870 polypeptide;
- and
- a pharmaceutically acceptable carrier.
A first Neisseria meningitidis (N. meningitidis) genetically modified to disrupt production of an endogenous GNA1870 polypeptide so that the endogenous GNA1870 is not present at detectable levels in antigenic vesicles prepared from the N. meningitidis and to express at least one heterologous full length meningococcal GNA1870 polypeptide.
Dependencies are inferred from the claim text.